Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.23.17 (
PCE
)
1,301
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Recent reports reveal that the C-terminal half of the neuroendocrine polypeptide
7B2
selectively inhibits and binds PC2, a mammalian
prohormone converting enzyme
that is homologous to the yeast pro-alpha-factor processing protease Kex2. During attempted secretion of the 185 amino-acid human
7B2
in Saccharomyces cerevisiae, we observe that the protein is mostly retained inside the cell. However a mutant polypeptide (
7B2
delta 1), where the C-terminal 48 amino acids of
7B2
are deleted, is efficiently secreted. Two shorter C-terminal truncations either permit poor secretion or no secretion at all. Surprisingly, full-length
7B2
but not
7B2
delta 1 abolishes the catalytic activity of Kex2, indicating that C-terminal residues of
7B2
might also be important for inhibition of the yeast protease. When the KEX2 gene is disrupted, yeast cells unexpectedly secrete a
7B2
variant similar in size to
7B2
delta 1, suggesting involvement of the alternate yeast prohormone convertase Yap3 in processing. Secretion is enhanced by overexpression of Yap3 and by the presence of a Lys-Arg residue at the processing site of precursor
7B2
. These results purport that, in neuroendocrine cells too, secretion of
7B2
could be mediated by a homologue of Yap3.
...
PMID:A C-terminal domain, which prevents secretion of the neuroendocrine protein 7B2 in Saccharomyces cerevisiae, inhibits Kex2 yet is processed by the Yap3 protease. 775 May 51